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in Patients with Malignant Pleural Mesothelioma
Loïc Lang-Lazdunski, MD, PhD, FRCS, Andrea Bille, MD, Elizabeth Belcher, MRCP, PhD, FRCS,
Paul Cane, FRCPath, David Landau, FRCP, Jeremy Steele, PhD, FRCP, Henry Taylor, FRCP,
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Introduction: Malignant pleural mesothelioma is a fatal neoplasm
related to asbestos exposure. We investigated the effects of pleurec-
tomy/decortication (P/D), hyperthermic pleural lavage with povi-
done-iodine and adjuvant chemotherapy in patients with malignant
pleural mesothelioma.
Patients and Methods: Observational prospective study of patients
referred for multimodality therapy and operated on at our institution
between October 2004 and May 2010. Thirty-six selected patients
underwent P/D and hyperthermic pleural lavage, prophylactic radio-
therapy, and adjuvant chemotherapy. All patients were reviewed at
4 weeks and then 6 monthly in the outpatient clinic, with positron-
emission tomography-computed tomography. Second-line treat-
ments were administered when appropriate.
Results: Thirty-day mortality was nil. Nine patients experienced
postoperative complications: persistent air leak (n  5, 13.9%),
chylothorax requiring surgical intervention (n  4, 11%), and adult
respiratory distress syndrome (n 1, 3.9%). Fourteen of 36 patients
were alive at last follow-up (median follow-up: 33 months, range:
12–63 months). Ten patients were alive with no evidence of disease
recurrence, four patients were alive with disease recurrence, and 22
patients had died of disease progression. Overall median survival
(Kaplan-Meier) was 24 months (95% confidence interval: 18.5–29.4
months). One-year survival was 91.7%, and 2-year survival was
61%. Patients undergoing complete macroscopical resection (R0–
R1) had a significantly better survival than those undergoing an
incomplete macroscopical resection (R2) (median overall survival:
32 months versus 18.9 months, p  0.012).
Conclusion: In our experience, P/D combined with hyperthermic
pleural lavage with povidone-iodine and adjuvant chemotherapy is a
well-tolerated multimodality treatment associated with low morbid-
ity and mortality. This multimodality treatment compares favorably
with classical trimodality regimens involving chemotherapy, extra-
pleural pneumonectomy, and adjuvant radiotherapy, in our experi-
ence. Study limitations include small sample size, nonrandomiza-
tion, and patient selection bias.
Key Words: Malignant pleura mesothelioma, Pleurectomy/decorti-
cation, Surgery, chemotherapy, Hyperthermic pleural lavage.
(J Thorac Oncol. 2011;6: 1746–1752)
Malignant pleural mesothelioma (MPM) remains a majorcause of death in patients exposed to asbestos.1 The
incidence of mesothelioma has raised continuously over the
past 20 years and is expected to peak around 2020 in Western
Europe.1
At present, there is no standard treatment for MPM, and
a majority of patients who present with recurrent pleural
effusion are offered palliative chemotherapy and talc pleu-
rodesis.2 Median survival after diagnosis is often less than 12
months.2,3 Those with early-stage disease and good perfor-
mance status are suitable for multimodality therapy involving
surgery, radiotherapy, and chemotherapy.4 Nevertheless,
such treatment is only feasible in well patients without
significant comorbidities.5 In practice, this subgroup of pa-
tient represents less than 20% of the total of those referred.
Multimodality therapy has evolved over the years.
Extrapleural pneumonectomy (EPP) has gained wide accep-
tance in the Western world following the favorable publica-
tions of Sugarbaker et al. and Rusch et al.5,6 showing pro-
longed survival in patients with epithelioid histology. A large
experience has now been accumulated by some institutions
offering neoadjuvant chemotherapy, EPP, and adjuvant ra-
diotherapy with 5-year survival rates approaching 50% in
patients with favorable prognostic factors such as epithelioid
histology and N0 disease, where complete resection has been
achieved.7–9 Although the 30-day mortality of EPP is pres-
ently less than 7% in most specialized centers, in most series,
less than 50% of patients complete the trimodality treatment
due to death or major complications.7–12 When patients re-
lapse after trimodality therapy, they usually die within 3
months due to lack of further effective treatment options.13
Pleurectomy/decortication (P/D) has long been used in
patients with MPM, and as early as 1976, Martini and
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coworkers14 reported a median survival of 21 months after
pleurectomy, adjuvant radiotherapy, and systemic chemother-
apy. More recently, similar outcomes have been reported in
patients treated with P/D and adjuvant radiotherapy plus
chemotherapy.15,16
The United Kingdom has the highest incidence of
mesothelioma worldwide, and our tertiary referral center has
an excess of 100 new mesothelioma cases referred annually.
Since 2003, we have offered EPP and P/D as part of our
multimodality therapy program. A significant proportion of
our patients are not suitable to undergo EPP or refuse EPP,
and we have, therefore, developed an alternative multimodal-
ity therapy plan for these patients based on P/D and hyper-
thermic pleural lavage followed by prophylactic radiotherapy
and adjuvant chemotherapy. This article presents our experi-
ence with this multimodality regimen.
PATIENTS AND METHODS
Since October 2004, all patients having P/D and hyper-
thermic pleural lavage followed by prophylactic radiotherapy
and adjuvant chemotherapy at our institution have been
studied prospectively.
Patients deemed suitable for multimodality therapy
were offered either neodjuvant chemotherapy, followed by
EPP and adjuvant radiotherapy (54 Gy) at 6 to 8 weeks or P/D
followed by prophylactic radiotherapy (21 Gy in three frac-
tions) at 4 to 6 weeks and adjuvant chemotherapy started at 6
weeks, postoperatively. Recruitment was by a specialized
multidisciplinary thoracic oncology meeting/clinic involving
thoracic surgeons, clinical oncologists, and medical oncolo-
gists. Histopathology and imaging review was undertaken in
all patients. Choice of multimodality treatment was deter-
mined by patient’s performance status, comorbidities, clinical
tumor, node, and metastasis (TNM) stage, histological sub-
type, and patient preference. Our policy was to offer radical
P/D to patients with epithelioid, biphasic, and sarcomatoid
histologies. A large proportion of patients were referred to
our unit for enrollment into the mesothelioma and radical
surgery trial involving EPP during the 2005–2008 period.10
Those patients not wishing to undergo EPP or to enroll into
the trial were offered the alternative treatment involving P/D
and pleural lavage, prophylactic radiotherapy, and adjuvant
chemotherapy. All patients received oral and written infor-
mation about mesothelioma treatments and were offered
several appointments to discuss their treatment plan. All
patients had chest computed tomography (CT) and 18-fluoro-
deoxyglucose-positron emission tomography (PET)-CT per-
formed before surgery to exclude patients with N3 disease or
extrathoracic metastases. Previous talc pleurodesis was not
regarded as a contraindication to the performance of P/D.
Nonbulky N2 disease was not regarded as a contraindication
to P/D in this study either. Only patients with performance
status 0 to 1 were offered multimodality therapy, and patients
with pejorative prognostic factors such as anemia, thrombo-
cytemia, high white blood cell count, weight loss were
excluded and referred for palliative chemotherapy. All pa-
tients had a pulmonary function test (spirometry and gas
transfer study) and those with a history of coronary artery
disease/angina had an echocardiogram and a coronary angio-
gram to rule out significant coronary artery disease. This
study was an observational prospective study.
Surgical Protocol
All patients were admitted the day before the surgical
procedure and were started on a single daily dose of enoxa-
parin (40 mg, subcutaneously) the night before surgery.
Patients received an epidural catheter before commencement
of the procedure. All patients had invasive arterial blood
pressure and central venous pressure monitoring. All patients
were operated on with a double-lumen tracheal tube, a naso-
gastric tube, and placed in the appropriate lateral decubitus
position with Ted stockings and pneumatic boots on through-
out the operation. All patients had pulse oximetry monitored
continuously and received prophylactic antibiotics (cefu-
roxime, three doses). All patients were monitored overnight
in a high dependency unit and returned to the thoracic
surgical ward on day 1 or later if appropriate.
The goal in all patients was to achieve maximal cytore-
duction and a complete macroscopic resection of the tumor
(R0 or R1). The approach was always a posterolateral thora-
cotomy through the 5th intercostal space. A partial rib resec-
tion (6th) was used in patients with contracted hemithorax. In
few patients, a second access thoracotomy was made in the
8th interspace to help achieve a complete resection of tumor
in the diaphragmatic recess or to resect and graft the dia-
phragm. Extrapleural dissection from the apex to the dia-
phragm and between the anterior and posterior pleural reflec-
tion was performed in all patients. Extended resection to
include the pericardium, lung parenchyma, and diaphragm
was undertaken as necessary. When the diaphragm was
involved (deep muscular invasion), it was resected and re-
constructed using a large polyfluorotetraethylene mesh
(2-mm Dual Mesh, Gore Tex, WL Gore and associates UK
Ltd, Livingston, West Lothian, UK). Complete decortication
of the lung was performed including the pulmonary fissures
down to the pulmonary artery and pleural reflections. Lymph-
adenectomy of the internal mammary chains and mediastinal
chains was routinely performed. The specimens were sent in
formalin for histopathology.
Once the P/D had been completed and the lung reex-
panded to check for air leaks, we performed a hyperthermic
pleural lavage (40–41°C) using sterile water mixed with 10%
povidone-iodine (Videne, Ecolab. Ltd., Lotherton Way Gart-
forth Leeds LS25 2JY, UK, dilution 1/10). In all patients, 5 to
6 L of water was used. The washout was allowed to bath in
the pleural cavity for 5 minutes while the lung was being
ventilated and was then aspirated. This maneuver was re-
peated three times. The thoracotomy wound was irrigated
with pure povidone-iodine before closure. A phrenic nerve
block (0.5% marcaine, 5 ml) was routinely done to prevent
shoulder pain. Two drains (28 F) were placed in the chest
cavity, and the thoracotomy was closed in layers. Extent of
resection and TNM stage was recorded by the operator.
Prophylactic Radiotherapy Protocol
All patients were reviewed in the outpatient clinic at 4
to 5 weeks postoperatively and referred for prophylactic
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radiotherapy (21 Gy in three daily fractions) on the thoracot-
omy, drain, and previous port sites according to Boutin’s
protocol.17
Adjuvant Chemotherapy Protocol
Adjuvant chemotherapy was started 6 to 8 weeks after
surgery, when the patient had recovered enough, and the
wounds had healed satisfactorily.
The regimen consisted of a combination of gemcitabine
and cisplatin before 2007, pemetrexed (500 mg/m2), and
cisplatin (75 mg/m2) thereafter.
The intent was to administer 4 to 6 cycles of chemo-
therapy. Most patients were treated as outpatients at our
institution and received their treatment 3 weekly in the
chemotherapy unit.
Patients were followed up in the outpatient clinic reg-
ularly and had PET-CT or chest CT arranged every 6 months
to monitor response to treatment or disease progression.
Those relapsing after multimodality therapy were offered
second-line treatment: combination chemotherapy with pem-
etrexed and cisplatin or single-agent vinorelbine or single-
agent Sorafenib as part of a phase I trial. Radiotherapy was
offered as a palliative measure when patients were diagnosed
with relapse, or as a curative treatment, exceptionally
(Cyberknife radiosurgery, 60 Gy in three daily fractions).
Statistical Analysis
Continuous data are reported with medians and ranges,
whereas categorical data are reported with counts and per-
centages. All potential prognostic indices were measured at
the time of operation and evaluated as categorical variables.
Survival curves were computed according to the Kaplan-
Meier method. Survival comparison between groups of pa-
tients undergoing radical P/D was performed using the log-
rank test. Factors significantly affecting survival were tested
in the univariate analysis. Confidence intervals (95%) were
used to quantify extend of the observed differences. Proba-
bility values less than 0.05 were considered statistically
significant. All analyses were conducted using the SPSS
(SPSS Inc., Chicago, IL) software package.
RESULTS
Forty-one patients had P/D performed by a single
surgeon (L.L.-L.) between November 2004 and May 2010.
Two patients who had empyema after video-assisted thora-
coscopic surgery talc pleurodesis were excluded retrospec-
tively due to the potential influence of empyema on the
natural history of malignant mesothelioma. Three patients
were excluded as they had received chemotherapy before P/D
or intrapleural gene therapy before P/D. A total of 36 patients
had P/D followed by prophylactic radiotherapy and adjuvant
chemotherapy.
Mean age at operation was 62.2 years (range: 46–73
years), and two patients were women (5.5%). Twenty-three
procedures were right sided and 13 left sided. Twenty pa-
tients (55.6%) underwent R0–R1 resection, whereas 16 un-
derwent R2 resection (45.4%). Extended resections included
diaphragm (n  4), lobectomy (n  3), segmentectomy (n 
2), and pericardectomy (n  2). There was no 30-day mor-
tality, and a few patients experienced postoperative compli-
cations: five patients (13.9%) had a persistent air leak, four
patients (11.1%) had chylothorax requiring thoracotomy (n
3) or video-assisted thoracoscopic surgery (n  1) to clip the
thoracic duct, and one patient had adult respiratory distress
syndrome (3.9%).
Final histopathology showed that 24 patients had epi-
thelioid mesothelioma (66.7%), 10 had biphasic mesotheli-
oma (27.8%), and two patients had sarcomatoid mesotheli-
oma (5.5%).
Twenty-six patients had N0 disease (72.2%), five pa-
tients had N1 disease (13.9%), and five patients had N2
disease (13.9%). Distribution was as follows: pT1N0M0, n
5; pT2N0M0, n  8; pT3N0M0, n  10; pT4N0M0, n  3;
pT3N1M0, n  4; pT4N1M0, n  1; pT2N2M0, n  3;
pT3N2M0, n  1; and pT4N2M0, n  1.
IMIG classification stages were I: n  5 (13.9%), II:
n  8 (22.2%), III: n  18 (50%), and IV: n  5 (13.9%),
respectively.
Thirty-five patients (97.2%) received the planned 4 to 6
cycles and completed the full multimodality therapy regimen.
One patient received two cycles of adjuvant chemotherapy
only together with prophylactic radiotherapy.
Three patients developed late complications after re-
ceiving first-line chemotherapy. One patient reaccumulated
fluid in the pleural cavity at 3 months after P/D and had a
pleurX catheter inserted, one had bronchopleural fistula after
adjuvant chemotherapy requiring and indwelling pleural cath-
eter (pleurX) for drainage, and another one underwent com-
pletion pneumonectomy for bronchopleural fistula at another
hospital 10 months after P/D. We did not observe wound
infections, pleural empyema, or patch infection in this series.
One patient suffered a pulmonary embolus shortly after his
fifth chemotherapy cycle and was anticoagulated. Twelve
patients received second-line treatment or are receiving sec-
ond-line treatment at last follow-up. Second-line treatment
included combination pemetrexed and cisplatin (n  2),
single-agent vinorelbine (n  5), or single-agent sorafenib as
part of a phase I trial (n  5). One patient diagnosed with
focal relapse of tumor at 1 year after P/D was treated with
cyberknife radiosurgery and remains disease free at 38
months. Of note, none of our patients was diagnosed with
chest wall tumor seeding at follow-up.
At last follow-up, 14 of 36 patients were alive (median
follow-up: 33 months, range: 12–63 months). Ten patients
were alive with no evidence of disease recurrence clinically
and on 18-fluoro-deoxyglucose-PET-CT, four patients were
alive with disease recurrence, and 22 patients have died of
disease progression. Overall median survival was 24 months
(95% confidence interval: 18.5–29.4) (Fig. 1). One-year sur-
vival was 91.7%, and 2-year survival was 61%. Univariate
analysis showed no significant difference when sex (p 0.4),
age 70 years (p  0.37), histological subtype—epithelioid
versus biphasic/sarcomatoid—(p  0.08) (Fig. 2), or side
(p  0.07) were considered. Nevertheless, completeness of
resection had a significant impact on survival, and patients
undergoing complete macroscopical resection (R0–R1) had
better survival than those who underwent an incomplete
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macroscopical resection (R2) (p  0.012) (Figure 3). When
macroscopic resection was complete, 1-year survival was
100%, 2-year survival was 83.9%, and median survival 32
months. When resection was incomplete, 1-year survival was
81.2%, 2-year survival was 31.6%, and median survival 18.9
months.
DISCUSSION
Five decades after the relationship between asbestos
and malignant mesothelioma was first described by Wagner,
MPM remains a major public health problem in the Western
world and a time bomb in the developing countries where
asbestos is still in use.1 At present, there is no recognized
curative treatment for MPM.10 Proponents of surgery suggest
that multimodality therapy involving EPP is associated with
significantly longer survival than palliative chemotherapy.
Recent retrospective series show 5-year survival rates ap-
proaching 50% in highly selected patients demonstrating
favorable prognostic factors.5,9 In most series, the informa-
tion was acquired retrospectively, and data were not collected
as “intention to treat.” Of note, in two recent prospective
trials, less than 55% of patients could complete the full
multimodality treatment plan.7,10 EPP is a “maximally-inva-
sive” procedure. Although mortality has fallen consistently
over time from 33% in the 1970s to less than 5% now at most
specialist centers,8,9,11,18 the morbidity associated with EPP
FIGURE 2. Survival by histology
(Kaplan-Meier).
FIGURE 1. Overall survival after multimodality
therapy (Kaplan-Meier).
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remains high with serious complications developing in more
than 50% of patients.11 Therefore, only fit patients and those
without comorbidities qualify for this operation. When pa-
tients have recovered from EPP, radical radiotherapy is ad-
ministered, and this can generate significant complications
and high mortality as well.12 The benefits of EPP seem to be
limited to patients with cN0/N1 disease and epithelioid sub-
type of mesothelioma.5 As most patients are diagnosed with
MPM in their sixth or seventh decade, many of them with
significant comorbidities such as coronary artery disease,
chronic obstructive pulmonary disease, diabetes, renal fail-
ure, and multimodality therapy involving EPP can only be
considered in a small proportion of patients. In our experience,
less than 20% of our referrals qualify for EPP on the basis of
performance status, age, and comorbidities. When histopathol-
ogy and TNM staging come into discussion, this number falls
lower than 15%.10 Finally, lack of treatment options after disease
recurrence after EPP and radiotherapy means that death usually
occurs within 3 months after recurrence.13
Opponents of radical surgery suggest that some patients
survive for several years without any treatment or with
palliative chemotherapy only after thoracoscopy/video-as-
sisted thoracoscopic surgery and talc pleurodesis. There are
anecdotal reports of spontaneous regression of MPM or very
prolonged survival without aggressive therapy.19 At present,
the standard of care for those unsuitable for multimodality
therapy is palliative chemotherapy with a combination of
pemetrexed and cisplatin.3 This regimen has been associated
with a 40% response rate and a median survival of 12 months
in a large randomized trial.3 Interestingly, a recent study
showed an equivalent median survival of 12.8 months in a
selected population of patients receiving multimodality therapy
involving EPP and hyperthermic intrapleural chemotherapy.20
Historical experiences with P/D showed acceptable
mortality and morbidity, especially when it was combined
with chemotherapy and radiotherapy.14,21 More recently, in-
hospital mortality rates around 2% and median survival
around 18 months after P/D and adjuvant chemotherapy,
whether hyperthermic pleural perfusion with chemotherapy
agents was used, have been reported.22,23 The addition of
adjuvant radiotherapy did not seem to confer any survival
advantage but was the source of radiation pneumonitis in a
large proportion of patients in two recent reports.16,24 Patterns
of relapse after EPP or P/D have been well studied and
described by Janne and Baldini.13 Although patients relapse
locally after P/D, patients seem to experience disease pro-
gression in the abdomen, mediastinum, contralateral lung,
and other distant sites after EPP.13
Our objective was to develop a surgical strategy suit-
able for most patients including those with biphasic histology
and those with N2 disease. Patients with sarcomatoid histol-
ogy have a dismal prognosis, no matter which treatment is
used, and it is now our belief that radical surgery should not
be offered in this group of patients. As virtually all patients
have residual microscopic disease after P/D, it seemed essen-
tial to prevent chest wall seeding by administering prophy-
lactic radiotherapy on the thoracotomy and drain wounds
according to Boutin’s protocol.17 We thought it was impor-
tant to obtain a maximal cytoreduction before administering
chemotherapy and used adjuvant rather than neoadjuvant
chemotherapy. Thus, cytoreductive surgery has been showed
to enhance the antitumoral immune response in a mouse
model, and we thought it could be beneficial to combine
enhanced antitumoral response and chemotherapy in our
patients.25
Povidone-iodine is a widely used antiseptic agent. Al-
though mainly used for skin preparation before surgery, some
have advocated its use to prevent tumoral seeding after
resection of colorectal carcinoma.26 Povidone-iodine has a
recognized antitumoral effect, and recently, Opitz et al.27
FIGURE 3. Survival by complete-
ness of macroscopic resection
(R0–R1 versus R2) (Kaplan-Meier).
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have showed that povidone-iodine has a direct cytotoxic
effect on mesothelioma cells and induces necrosis of meso-
thelioma cells in vitro. We cannot speculate on the impact of
povidone-iodine lavage on patient’s survival in our short series.
Nevertheless, it is important to note that none of our patients had
wound infection, empyema, or chest wall seeding.
Cytoreductive surgery and hyperthermic intraoperative
intraperitoneal chemotherapy have showed encouraging re-
sults in large series of patients with peritoneal mesothelioma,
and hyperthermia is known to enhance the effect of chemo-
therapy agents.28 Preliminary experiences in MPM have been
rather disappointing, and survival with this technique does
not seem to be better than after simple P/D.23 Pleural perfu-
sion requires a roller pump and a bypass circuit, a perfusion-
ist, and a qualified chemotherapy pharmacist to prepare and
administer the chemotherapy agents. Renal function, hemat-
ocrit, and other variables have to be monitored during and
after the procedure. Moreover, severe complications such as
permanent renal failure, bronchopleural fistula, postoperative
empyema, and wound dehiscence have been associated with
the use of hyperthermic pleural perfusion with cisplatin.20,29
Mortality has varied from nil to 11% after P/D and hyper-
thermic intrapleural chemotherapy.23,29 Postoperative mor-
bidity was 41% and 65% in two recent series.23,29 Median
survival was 11 months in the Dutch series and 13 months in
the American series.23,29 Our mortality, morbidity, and me-
dian survival compare favorably with those series and suggest
that instead of offering a survival advantage, hyperthermic
intrapleural chemotherapy might be detrimental.
Considering the interesting effect of povidone-iodine,
its wide availability, and the risk and complexity associated
with intrapleural chemotherapy, we decided to design a
protocol involving moderate hyperthermia (40–41°C), sim-
ple pleural lavage, and a moderate dose of povidone-iodine.
We have been using povidone-iodine lavage for more than 15
years to induce pleurodesis after pleural abrasion in young
patients with recurrent spontaneous pneumothorax without
any adverse side effects. A recent publication reported cases
of permanent blindness after intrapleural administration of
povidone-iodine; however, we believe this to be product-
related rather than the povidone-iodine itself.30
Although quality of life data were not collated, treat-
ment acceptance and tolerance were good, and indeed all
patients received all three treatment modalities. As others, we
were somehow disappointed by the recurrence rate after P/D
and chemotherapy, and this is something we must concentrate
on in the future. Immunotherapy trials or new targeted ther-
apies could be combined with P/D or administered after P/D
and help tackle microscopic disease and get better local
control in the future.
Completeness of resection is an important prognostic
factor, and patients having incomplete resection (R2) do
poorly on follow-up. In this series, our goal was to achieve a
complete macroscopic resection in all patients (R0–R1). The
limitations were the degree of invasion of the lung parenchyma,
diaphragm, and mediastinum. P/D can be easily performed in
patients with stage I mesothelioma and with more difficulties in
patients with stage II and stage III mesothelioma where a lung
resection (up to lobectomy), pericardectomy, or diaphragmatic
resection have to be performed sometimes to achieve complete
macroscopic clearance.
We do recognize that our study suffers several limita-
tions including small sample size, nonrandomization, and
patient selection bias based on prognostic factors. Further
randomized studies are warranted to assess the effectiveness
of this multimodality regimen versus chemotherapy only, the
only established standard of care in MPM. Based on our
experience and on others, we are planning to start soon a
large randomized controlled trial assessing the role of radical
P/D and adjuvant chemotherapy versus chemotherapy only in
patients with MPM.
CONCLUSION
In our experience, P/D with hyperthermic pleural la-
vage with povidone-iodine and adjuvant chemotherapy is a
well-tolerated multimodality scheme. It is associated with
low morbidity and mortality. This treatment plan could rep-
resent an alternative to the classical trimodality regimen
involving chemotherapy, EPP, and adjuvant radiotherapy if
our results were to be confirmed in larger trials and by other
groups. Further studies are warranted to compare this treatment
protocol to chemotherapy only and make sure that radical P/D
can significantly improve life expectancy. Further treatments are
needed to reduce local recurrence after radical P/D.
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